“Pfizer is ready to produce a vaccine for the new variant in about 100 days, if needed,” Albert Burla reiterated.
“From studies of the Beta and Delta variants, we have developed an approach to developing and producing variations of our vaccine in about 100 days, if needed, with appropriate regulatory approval,” he said in a Twitter post on Tuesday.
At the same time, the head of Pfizer upgraded his estimates for the amount of antiviral pill that Pfizer can produce.
“If approved, we are confident that our oral antiviral therapy can help reduce the severity of the disease, and we now expect to be able to deliver 80 million doses, up from our initial estimate of 50 million,” he said in another post. .
He clarifies that at this stage coronavirus vaccination is the best solution.
“However, we believe that the best protection against the spread of the Omicron variant and any new variation that may occur is to fully vaccinate all eligible individuals with the third dose, as recommended,” said the head of the pharmaceutical giant.
We are prepared to tackle a variant like Omicron. From studies of the Beta & Delta variants, we established an approach to develop and produce variant versions of our vaccine in ~100 days, if needed, and subject to regulatory approval.
— Albert Bourla (@AlbertBourla) November 30, 2021
Follow Skai.gr on Google News
and be the first to know all the news
.
